Skip to main content

Table 1 Clinical and demographic features of study population at baseline

From: Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?

  EM CM-MO p-value
n 27 28
Age 39.2 ± 8.8 47.6 ± 10.9 0.002
Sex (female) 25 (92.6%) 24 (85.7%) 0.669
Duration of migraine (years) 22.6 ± 9.7 30.8 ± 12.1 0.013
Duration of chronic migraine (years) 12.2 ± 10.8
Duration of medication overuse (years) 8.6 ± 6.4
Migraine days per month 6.9 ± 2.4 23.6 ± 5.3 0.001
Headache days per month 7.2 ± 2.4 26.2 ± 5.2 0.001
Days of acute drug intake per month 6.7 ± 2.2 23.2 ± 5.6 0.001
Doses of acute drugs per month 7.2 ± 2.7 51.5 ± 60.5 0.001
Migraine with aura 5 (18.5%) 7 (25.0%) 0.746
Preventive therapy at baseline 10 (37.0%) 10 (35.7%) 1.000
Previous detoxification 32.1%
Acute treatment
NSAID 13 (48.1%) 14 (50.0%) 0.845
Triptan 8 (29.6%) 7 (25.0%)
Combination 4 (14.8%) 6 (21.4%)
Politherapy 2 (7.4%) 1 (3.6%)
  1. Legend: EM episodic migraine, CM-MO chronic migraine with medication overuse, NSAID nonsteroidal anti-inflammatory drugs. Continuous variables are presented as mean ± standard deviation